Does CYP2C19*17 genotyping have clinical utility?
CYP2C19*17 genotyping is unlikely to be clinically useful except for drugs with very narrow therapeutic indices.
Assignment of CYP2C19*17 homozygotes as extensive metabolizers rather than ultrarapid metabolizers is adequate. CYP2C19*17 genotyping is unlikely to have clinical utility except for drugs with very narrow therapeutic indices.
Li‐Wan‐Po et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: